Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Cagrilintide

INVESTIGATIONAL

Long-acting amylin analogue

7
graded results
0
ongoing records
5
effect domains
Evidence spread
High evidence 0Moderate evidence 5Low evidence 1Very low evidence 1

Cagrilintide is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Obesity; Subcutaneous injection; as of 2026-07-13. ClinicalTrials.gov

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Cagrilintide INVESTIGATIONAL
weight-loss Decrease
Moderate evidence

Once-weekly cagrilintide monotherapy produced dose-dependent weight loss in adults with overweight/obesity; 4.5 mg gave ~10.8% (~11.5 kg) at 26 weeks vs ~3.0% placebo,...

Lau et al., Lancet 2021 (phase 2); Novo Nordisk REDEFINE 1, NEJM 2025 Source
Full findingOnce-weekly cagrilintide monotherapy produced dose-dependent weight loss in adults with overweight/obesity; 4.5 mg gave ~10.8% (~11.5 kg) at 26 weeks vs ~3.0% placebo, curves not plateaued. As a 2.4 mg monotherapy arm within REDEFINE 1 (68 wk, T2D-free), cagrilintide alone gave 11.5% mean weight reduction.
Populationphase 2: adults overweight/obesity, 0.3-4.5 mg, 26 wk, placebo-controlled; REDEFINE 1: cagrilintide 2.4 mg arm within 3,417 adults, 68 wk
Fundingindustry - Novo Nordisk
Comparatorsplacebo; liraglutide 3.0 mg (phase 2); semaglutide 2.4 mg (REDEFINE 1); CagriSema (REDEFINE 1)
Cagrilintide INVESTIGATIONAL
weight-loss Decrease
Moderate evidence

Dose-dependent weight loss; 4.5 mg superior to liraglutide 3.0 mg over 26 wk

Lau DCW et al. Lancet 2021;398:2160-2172 Source
PopulationAdults overweight/obese without diabetes (n=706 cagrilintide), phase 2 dose-finding, 26 wk, RCT double-blind placebo+active controlled (NCT03856047)
Fundingindustry - Novo Nordisk
Comparatorsplacebo; liraglutide 3.0 mg
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Cagrilintide INVESTIGATIONAL
appetite-intake Decrease
Moderate evidence

Once-weekly cagrilintide (0.3-4.5 mg, 26 wk) produced dose-dependent weight loss greater than placebo and greater than liraglutide 3.0 mg at the top dose in adults...

Lau DCW et al. Lancet 2021;398:2160-2172 Source
Full findingOnce-weekly cagrilintide (0.3-4.5 mg, 26 wk) produced dose-dependent weight loss greater than placebo and greater than liraglutide 3.0 mg at the top dose in adults with overweight/obesity without diabetes; amylin's mechanism is satiety induction via homeostatic and hedonic brain regions. Ad libitum energy intake was not the trial endpoint; weight loss is the downstream integral.
PopulationAdults with overweight/obesity without diabetes, n=706 cagrilintide, 26 weeks (NCT03856047)
Fundingindustry - Novo Nordisk
Comparatorsplacebo; liraglutide 3.0 mg
Cagrilintide INVESTIGATIONAL
appetite-intake Decrease
Very low evidence

A cross-species (rat/mouse/macaque/human) dorsal vagal complex atlas defined amylin-receptor (Calcr) neuronal mediators of cagrilintide's energy-balance effects:...

Ludwig MQ et al., Nat Metab 2026 (advance online) Source
Full findingA cross-species (rat/mouse/macaque/human) dorsal vagal complex atlas defined amylin-receptor (Calcr) neuronal mediators of cagrilintide's energy-balance effects: long-term cagrilintide upregulates prolactin-releasing hormone (Prlh) in conserved NTS Calcr/Prlh cells, and knocking down DVC Prlh abrogates cagrilintide's (but not semaglutide's) effect on food intake/body weight in rats — a mechanistic substrate for amylin-driven intake suppression.
PopulationRat (primary functional), with mouse/macaque/human transcriptomic mapping
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Comparatorsvehicle; semaglutide (comparator agonist)
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Cagrilintide INVESTIGATIONAL
glycaemic Decrease
Moderate evidence

As monotherapy in T2D, HbA1c reduction smaller than semaglutide or CagriSema

Frias JP et al. Lancet 2023;402:720-730 Source
PopulationT2D BMI ≥27 on metformin±SGLT2i (n=30 cagrilintide arm), phase 2, 32 wk, RCT (NCT04982575)
Fundingindustry-Novo Nordisk
Comparatorssemaglutide 2.4 mg; CagriSema
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Cagrilintide INVESTIGATIONAL
pharmacology Not directional
Low evidence

Long-acting amylin analogue, once-weekly; half-life 159-195 h; PK dose-proportional and independent of co-dosed semaglutide

Enebo LB et al. Lancet 2021;397:1736-1748 Source
PopulationHealthy overweight (n=96), phase 1b co-administration with semaglutide 2.4 mg (NCT03600480)
Fundingindustry - Novo Nordisk (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Cagrilintide INVESTIGATIONAL
Stomach and gut Increase
Moderate evidence

GI disorders and injection-site reactions most frequent; more than placebo

Lau DCW et al. Lancet 2021;398:2160-2172 Source
PopulationOverweight/obese (n=706), phase 2, 26 wk
Fundingindustry - Novo Nordisk
Comparatorsplacebo; liraglutide 3.0 mg